palmitoylethanolamide.com.au
HomeResearchArash 2021

The immune system and autism spectrum disorder: association and therapeutic challenges

Arash Heidari, Yasna Rostam-Abadi, Nima Rezaei. Acta Neurobiol Exp (Wars). 2021;81(3):249-263.

ReviewHumans

Design
Review
Subjects
Not stated in the abstract
Dose used in the study
Not stated in the abstract
Duration
Not stated in the abstract
What was measured
Whether immune and autoimmune dysfunction contributes to autism spectrum disorder, and what anti-inflammatory agents, including palmitoylethanolamide, have been reported to do about it.

What the authors reported

Immune involvement in autism spectrum disorder shows up as microbiome and gut-brain axis changes, higher pro-inflammatory cytokines in patients, and more autoimmune disorders in first-degree relatives. Anti-inflammatory agents, including resveratrol and palmitoylethanolamide, have been reported to relieve manifestations of autism, though the authors say stronger studies are needed.

Limits of this study

A narrative review with no new data and no trial numbers for palmitoylethanolamide. Funding and conflicts not stated in the abstract.

Source

PubMed 34672295 · doi:10.21307/ane-2021-023

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.